For example, the presence of IDH1 mutations and 1p/19q co-deletions are associated with better survival outcomes for grade II, III, and IV gliomas [7,23,26,27], which may be relevant for determining treatment options for lower grade glioma patients with worse prognoses [7,26]. The gene discussed is IDH1; the disease is central nervous system cancer.